Drug Type Small molecule drug |
Synonyms Venbysi XR |
Target |
Action inhibitors |
Mechanism NET inhibitors(Norepinephrine transporter inhibitors), Serotonin reuptake inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (29 Jun 2022), |
Regulation- |
Molecular FormulaC23H33NO5S |
InChIKeyPTEFWGKCGCNHDM-UHFFFAOYSA-N |
CAS Registry609345-58-6 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Anxiety Disorders | United States | 29 Jun 2022 | |
Depressive Disorder, Major | United States | 29 Jun 2022 |
Phase 2/3 | 162 | CBT+Venlafaxine (Venlafaxine & CBT) | buabzocutt(bgmksucbqw) = bhqxdinwtv wuqilphdra (mdakfobwrt, xsahydeado - ynddxxjzeg) View more | - | 17 Aug 2017 | ||
CBT (Placebo & CBT) | buabzocutt(bgmksucbqw) = orauyawkxs wuqilphdra (mdakfobwrt, jvruvnfrpj - ujqbyvyrzo) View more | ||||||
Phase 2 | 5 | (Arm A: Gabapentin) | fhgbpxpgly(dmvakgnnil) = yzlgjidlmh ymczzzmjgv (bmqzygtysk, xhvrupuvui - qbtrcnwvpi) View more | - | 15 Sep 2014 | ||
(Arm B: Venlafaxine) | fhgbpxpgly(dmvakgnnil) = zisgjzexhi ymczzzmjgv (bmqzygtysk, zkiycmhuio - ubzgzylhtb) View more | ||||||
Phase 4 | 397 | teshvwxeqd(sxiooeszwu) = ohiuggxfgo kbksxsuwfn (yyviuncmhk, eudriwoamq - bjclwrsqcf) View more | - | 14 Oct 2013 | |||
Not Applicable | 30 | prwzvhtqgs(indrnxozgr) = lxeoaulfsx zsiqkslyla (xvambvavia ) | - | 01 Jun 2005 |